Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined r...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2012-10, Vol.59 (4), p.756-757
Main Authors: Watt, Tanya C., Cooper, Todd
Format: Article
Language:English
Subjects:
Adolescent
AML
Antineoplastic Agents - therapeutic use
Benzenesulfonates - therapeutic use
Child
Female
Humans
Leukemia, Myeloid, Acute - drug therapy
Male
Niacinamide - analogs & derivatives
pediatrics
Phenylurea Compounds
Protein Kinase Inhibitors - therapeutic use
Pyridines - therapeutic use
Recurrence
relapse
Remission Induction
sorafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643
cites cdi_FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643
container_end_page 757
container_issue 4
container_start_page 756
container_title Pediatric blood & cancer
container_volume 59
creator Watt, Tanya C.
Cooper, Todd
description The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756–757. © 2011 Wiley Periodicals, Inc.
doi_str_mv 10.1002/pbc.23394
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pbc_23394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PBC23394</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643</originalsourceid><addsrcrecordid>eNp1kMlOwzAURS0EoqWw4AeQtyzSeogzLGkEBalMKsPSsp0XFJo0kZ0I8veEhnbH6t3FuVdPB6FzSqaUEDartZkyzmP_AI2p8IUnCA0P95nEI3Ti3GePBkREx2jEGBFMCDZGb6vKqgw2ucbK4caCakrYNDirLLZQqNpBirc5s8o0le1wDWmuGpsbrEzbAC47KKoP2FStwwW0ayhzdYqOMlU4OPu7E_R6c_2S3HrLx8VdcrX0DOfE91TEhO5DCD4Jo8hXOkhN_5sm1E8F0IjpLIuFpmEkQl8zFYdBzFNtQHFqAp9P0OWwa2zlXP-krG1eKttJSuSvG9m7kVs3PXsxsHWrS0j35E5GD8wG4CsvoPt_ST7Nk92kNzRy18D3vqHsWgYhD4V8f1jIKEjo6n7-LBP-AzKpfYY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Watt, Tanya C. ; Cooper, Todd</creator><creatorcontrib>Watt, Tanya C. ; Cooper, Todd</creatorcontrib><description>The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756–757. © 2011 Wiley Periodicals, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.23394</identifier><identifier>PMID: 22052552</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; AML ; Antineoplastic Agents - therapeutic use ; Benzenesulfonates - therapeutic use ; Child ; Female ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Male ; Niacinamide - analogs &amp; derivatives ; pediatrics ; Phenylurea Compounds ; Protein Kinase Inhibitors - therapeutic use ; Pyridines - therapeutic use ; Recurrence ; relapse ; Remission Induction ; sorafenib</subject><ispartof>Pediatric blood &amp; cancer, 2012-10, Vol.59 (4), p.756-757</ispartof><rights>Copyright © 2011 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643</citedby><cites>FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22052552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watt, Tanya C.</creatorcontrib><creatorcontrib>Cooper, Todd</creatorcontrib><title>Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia</title><title>Pediatric blood &amp; cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756–757. © 2011 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>AML</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzenesulfonates - therapeutic use</subject><subject>Child</subject><subject>Female</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Male</subject><subject>Niacinamide - analogs &amp; derivatives</subject><subject>pediatrics</subject><subject>Phenylurea Compounds</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyridines - therapeutic use</subject><subject>Recurrence</subject><subject>relapse</subject><subject>Remission Induction</subject><subject>sorafenib</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kMlOwzAURS0EoqWw4AeQtyzSeogzLGkEBalMKsPSsp0XFJo0kZ0I8veEhnbH6t3FuVdPB6FzSqaUEDartZkyzmP_AI2p8IUnCA0P95nEI3Ti3GePBkREx2jEGBFMCDZGb6vKqgw2ucbK4caCakrYNDirLLZQqNpBirc5s8o0le1wDWmuGpsbrEzbAC47KKoP2FStwwW0ayhzdYqOMlU4OPu7E_R6c_2S3HrLx8VdcrX0DOfE91TEhO5DCD4Jo8hXOkhN_5sm1E8F0IjpLIuFpmEkQl8zFYdBzFNtQHFqAp9P0OWwa2zlXP-krG1eKttJSuSvG9m7kVs3PXsxsHWrS0j35E5GD8wG4CsvoPt_ST7Nk92kNzRy18D3vqHsWgYhD4V8f1jIKEjo6n7-LBP-AzKpfYY</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Watt, Tanya C.</creator><creator>Cooper, Todd</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201210</creationdate><title>Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia</title><author>Watt, Tanya C. ; Cooper, Todd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>AML</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzenesulfonates - therapeutic use</topic><topic>Child</topic><topic>Female</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Male</topic><topic>Niacinamide - analogs &amp; derivatives</topic><topic>pediatrics</topic><topic>Phenylurea Compounds</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyridines - therapeutic use</topic><topic>Recurrence</topic><topic>relapse</topic><topic>Remission Induction</topic><topic>sorafenib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watt, Tanya C.</creatorcontrib><creatorcontrib>Cooper, Todd</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric blood &amp; cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watt, Tanya C.</au><au>Cooper, Todd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia</atitle><jtitle>Pediatric blood &amp; cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2012-10</date><risdate>2012</risdate><volume>59</volume><issue>4</issue><spage>756</spage><epage>757</epage><pages>756-757</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756–757. © 2011 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22052552</pmid><doi>10.1002/pbc.23394</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1545-5009
ispartof Pediatric blood & cancer, 2012-10, Vol.59 (4), p.756-757
issn 1545-5009
1545-5017
language eng
recordid cdi_crossref_primary_10_1002_pbc_23394
source Wiley-Blackwell Read & Publish Collection
subjects Adolescent
AML
Antineoplastic Agents - therapeutic use
Benzenesulfonates - therapeutic use
Child
Female
Humans
Leukemia, Myeloid, Acute - drug therapy
Male
Niacinamide - analogs & derivatives
pediatrics
Phenylurea Compounds
Protein Kinase Inhibitors - therapeutic use
Pyridines - therapeutic use
Recurrence
relapse
Remission Induction
sorafenib
title Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A42%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sorafenib%20as%20treatment%20for%20relapsed%20or%20refractory%20pediatric%20acute%20myelogenous%20leukemia&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Watt,%20Tanya%20C.&rft.date=2012-10&rft.volume=59&rft.issue=4&rft.spage=756&rft.epage=757&rft.pages=756-757&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.23394&rft_dat=%3Cwiley_cross%3EPBC23394%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3304-a825b3047e407884ab6dc205b014d5e182bff95b178574b2a97693dbcea31c643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22052552&rfr_iscdi=true